6533b7d3fe1ef96bd125ffcb

RESEARCH PRODUCT

Chemotherapy in advanced pancreatic cancer

Wolfgang DippoldHelga BernhardK H Meyer Zum Büschenfelde

subject

Oncologymedicine.medical_specialtyNauseamedicine.medical_treatmentContext (language use)GastroenterologyFolinic acidEndocrinologyPancreatic cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansChemotherapybusiness.industryGastroenterologyCombination chemotherapymedicine.diseasePancreatic NeoplasmsRadiation therapyOncologyFluorouracilmedicine.symptombusinessProgressive diseasemedicine.drug

description

Patients with advanced adenocarcinomas of the pancreas have an exceptionally poor prognosis. Modest activity has been demonstrated with single agents (response rates of 25% at best with 5-fluorouracil [5-FU] and mitomycin). Better results have not been obtained by combination chemotherapy. Improvements in the palliation have been achieved by treatment with 5-FU, folinic acid (FA), and interferon-alpha-2A (IFN-alpha) weekly in the context of a phase II trial. Of 57 evaluable patients, eight (14%) had a partial response (PR), eight (14%) a minor response (MR), and 28 (49%) had no change of disease (NC). The median survival time was 10 mo for patients with progressive disease. Twenty-two out of 36 patients with tumor-related pain whose tumors were affected in terms of PR, MR, and NC became free of pain during treatment. Fever (56%), nausea (37%), and diarrhea (33%) were common toxicities observed. Therefore, biochemical modulation of 5-FU with FA and IFN-alpha shows some positive effects in the treatment of pancreatic cancer with moderate toxicity.

yearjournalcountryeditionlanguage
1997-02-01International journal of pancreatology
https://doi.org/10.1007/bf02785918